{"name":"Region Örebro County","slug":"region-rebro-county","ticker":"","exchange":"","domain":"regionorebrolan.se","description":"","hq":"Örebro","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"FSME-IMMUN Vaccine","genericName":"FSME-IMMUN Vaccine","slug":"fsme-immun-vaccine","indication":"Prevention of tick-borne encephalitis (TBE) in endemic areas","status":"marketed"},{"name":"Local application of collagen-gentamicin","genericName":"Local application of collagen-gentamicin","slug":"local-application-of-collagen-gentamicin","indication":"Other","status":"phase_1"},{"name":"Placebo Tab","genericName":"Placebo Tab","slug":"placebo-tab","indication":"Control arm in phase 3 clinical trials (non-therapeutic use)","status":"phase_3"},{"name":"PlaceboMNTX","genericName":"PlaceboMNTX","slug":"placebomntx","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"I/T morphine","genericName":"I/T morphine","slug":"i-t-morphine","indication":"Chronic pain management via intrathecal delivery","status":"marketed"},{"name":"CDK 4/6 inhibitors","genericName":"CDK 4/6 inhibitors","slug":"cdk-4-6-inhibitors","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"RemifentanilMNTX","genericName":"RemifentanilMNTX","slug":"remifentanilmntx","indication":"Intraoperative analgesia and sedation during anesthesia","status":"marketed"},{"name":"ropivacaine, ketorelac and epinephrine","genericName":"ropivacaine, ketorelac and epinephrine","slug":"ropivacaine-ketorelac-and-epinephrine","indication":"Postoperative pain management","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Clonidine Oral Liquid Product","genericName":"Clonidine Oral Liquid Product","slug":"clonidine-oral-liquid-product","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"I/T morphine","genericName":"I/T morphine","slug":"i-t-morphine","phase":"marketed","mechanism":"Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation.","indications":["Chronic pain management via intrathecal delivery","Cancer pain","Post-operative pain"],"catalyst":""},{"name":"CDK 4/6 inhibitors","genericName":"CDK 4/6 inhibitors","slug":"cdk-4-6-inhibitors","phase":"phase_3","mechanism":"CDK 4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)","Hormone receptor-positive, HER2-negative early breast cancer (adjuvant setting, in combination with endocrine therapy)"],"catalyst":""},{"name":"Clonidine Oral Liquid Product","genericName":"Clonidine Oral Liquid Product","slug":"clonidine-oral-liquid-product","phase":"marketed","mechanism":"Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity by stimulating alpha-2 receptors in the brain and periphery.","indications":["Hypertension","Attention-deficit/hyperactivity disorder (ADHD)","Opioid withdrawal"],"catalyst":""},{"name":"FSME-IMMUN Vaccine","genericName":"FSME-IMMUN Vaccine","slug":"fsme-immun-vaccine","phase":"marketed","mechanism":"FSME-IMMUN is an inactivated tick-borne encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against TBEV.","indications":["Prevention of tick-borne encephalitis (TBE) in endemic areas"],"catalyst":""},{"name":"Local application of collagen-gentamicin","genericName":"Local application of collagen-gentamicin","slug":"local-application-of-collagen-gentamicin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Tab","genericName":"Placebo Tab","slug":"placebo-tab","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect, serving as an inert control to measure the psychological and contextual benefits of treatment.","indications":["Control arm in phase 3 clinical trials (non-therapeutic use)"],"catalyst":""},{"name":"PlaceboMNTX","genericName":"PlaceboMNTX","slug":"placebomntx","phase":"marketed","mechanism":"PlaceboMNTX is a placebo formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"RemifentanilMNTX","genericName":"RemifentanilMNTX","slug":"remifentanilmntx","phase":"marketed","mechanism":"RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects.","indications":["Intraoperative analgesia and sedation during anesthesia"],"catalyst":""},{"name":"ropivacaine, ketorelac and epinephrine","genericName":"ropivacaine, ketorelac and epinephrine","slug":"ropivacaine-ketorelac-and-epinephrine","phase":"phase_3","mechanism":"Ropivacaine is a local anesthetic that blocks nerve impulses, while ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation, and epinephrine is a vasoconstrictor that helps to prolong the duration of action of ropivacaine.","indications":["Postoperative pain management","Pain management during labor and delivery"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":9,"phaseCounts":{"marketed":5,"phase_3":3,"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}